Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma

Karen Juul Mylam; Anne Lerberg Nielsen; Lars Møller Pedersen; Martin Hutchings

doi:10.1016/j.cpet.2014.06.001

Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma

Karen Juul Mylam, Anne Lerberg Nielsen, Lars Møller Pedersen, Martin Hutchings

4 Citationer (Scopus)

Abstract

Diffuse large B-cell lymphoma (DLBCL) is an aggressive and potentially curable type of lymphoma. Fluorine-18-fluorodeoxyglucose positron emission tomography (FDG-PET) is part of clinical routine for DLBCL in most hospitals and also recommended for staging and end-of-therapy evaluation. FDG-PET/computed tomography (CT) is able to identify nodal and extranodal sites with greater accuracy than CT alone. Little evidence supports the use of surveillance FDG-PET imaging in the follow-up setting because of high rates of false-positive scans and because most studies are retrospective. This article discusses FDG-PET assessment methods and the clinical application of FDG-PET for management of DLBCL.

Originalsprog	Engelsk
Tidsskrift	P E T Clinics
Vol/bind	9
Udgave nummer	4
Sider (fra-til)	443-55, vi
ISSN	1556-8598
DOI	https://doi.org/10.1016/j.cpet.2014.06.001
Status	Udgivet - okt. 2014

Adgang til dokumentet

10.1016/j.cpet.2014.06.001

Citationsformater

@article{9a99b168ac3f4a7fa30bab2839d3c994,

title = "Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma",

abstract = "Diffuse large B-cell lymphoma (DLBCL) is an aggressive and potentially curable type of lymphoma. Fluorine-18-fluorodeoxyglucose positron emission tomography (FDG-PET) is part of clinical routine for DLBCL in most hospitals and also recommended for staging and end-of-therapy evaluation. FDG-PET/computed tomography (CT) is able to identify nodal and extranodal sites with greater accuracy than CT alone. Little evidence supports the use of surveillance FDG-PET imaging in the follow-up setting because of high rates of false-positive scans and because most studies are retrospective. This article discusses FDG-PET assessment methods and the clinical application of FDG-PET for management of DLBCL.",

author = "Mylam, {Karen Juul} and Nielsen, {Anne Lerberg} and Pedersen, {Lars M{\o}ller} and Martin Hutchings",

year = "2014",

month = oct,

doi = "10.1016/j.cpet.2014.06.001",

language = "English",

volume = "9",

pages = "443--55, vi",

journal = "P E T Clinics",

issn = "1556-8598",

publisher = "W.B. Saunders",

number = "4",

}

TY - JOUR

T1 - Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma

AU - Mylam, Karen Juul

AU - Nielsen, Anne Lerberg

AU - Pedersen, Lars Møller

AU - Hutchings, Martin

PY - 2014/10

Y1 - 2014/10

N2 - Diffuse large B-cell lymphoma (DLBCL) is an aggressive and potentially curable type of lymphoma. Fluorine-18-fluorodeoxyglucose positron emission tomography (FDG-PET) is part of clinical routine for DLBCL in most hospitals and also recommended for staging and end-of-therapy evaluation. FDG-PET/computed tomography (CT) is able to identify nodal and extranodal sites with greater accuracy than CT alone. Little evidence supports the use of surveillance FDG-PET imaging in the follow-up setting because of high rates of false-positive scans and because most studies are retrospective. This article discusses FDG-PET assessment methods and the clinical application of FDG-PET for management of DLBCL.

AB - Diffuse large B-cell lymphoma (DLBCL) is an aggressive and potentially curable type of lymphoma. Fluorine-18-fluorodeoxyglucose positron emission tomography (FDG-PET) is part of clinical routine for DLBCL in most hospitals and also recommended for staging and end-of-therapy evaluation. FDG-PET/computed tomography (CT) is able to identify nodal and extranodal sites with greater accuracy than CT alone. Little evidence supports the use of surveillance FDG-PET imaging in the follow-up setting because of high rates of false-positive scans and because most studies are retrospective. This article discusses FDG-PET assessment methods and the clinical application of FDG-PET for management of DLBCL.

U2 - 10.1016/j.cpet.2014.06.001

DO - 10.1016/j.cpet.2014.06.001

M3 - Journal article

C2 - 26050946

SN - 1556-8598

VL - 9

SP - 443-55, vi

JO - P E T Clinics

JF - P E T Clinics

IS - 4

ER -

Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater